Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

The OncFive: Top Oncology Articles for the Week of 11/10

November 16th 2024

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy

November 11th 2024

RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

November 11th 2024

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

November 7th 2024

Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.

Dr Truong on the Background of the ImmunoCobiVem Trial in BRAF V600+ Melanoma

November 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Ameluz-PDT Leads to Target Lesion Clearance in Superficial Basal Cell Carcinoma

November 1st 2024

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced Melanoma

October 30th 2024

Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

October 10th 2024

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Dr Truong on Targeted Therapy vs Immunotherapy in BRAF V600–Positive Melanoma

October 7th 2024

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.

Dr Van Akkooi on the Prognostic Value of Minimal Sentinel Node Tumor Burden in Melanoma

September 26th 2024

Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.

Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced Melanoma

September 26th 2024

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works

September 18th 2024

Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

September 16th 2024

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS in BRAF V600–Positive Melanoma

September 15th 2024

Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

September 15th 2024

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.

Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma

September 15th 2024

Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.

Nivolumab Alone, With Ipilimumab Demonstrate Sustained 10-Year Survival Benefit in Advanced Melanoma

September 15th 2024

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.